Abstracts tagged "Rheumatoid Factor"

Abstract Number: 2983 • 2018 ACR/ARHP Annual Meeting
The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
Nathalie Carrier¹, Sophie Roux², Ariel Masetto², Artur J deBrum Fernandes³, Patrick Liang⁴, Meryem Maoui⁵ and Gilles Boire⁴, ¹Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Bristol-Myers Squibb Canada., St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution of baseline demographic, clinical, serological and genetic characteristics of patients with incident RA over 20 years. Methods: Since July 1998,…
Abstract Number: 87 • 2018 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients with Circulating Extracellular Vesicles Positive for IgM Rheumatoid Factor Have Higher Disease Activity
Onno J. Arntz¹, Bartijn C.H. Pieters¹, Rogier Thurlings², Peter M. van der Kraan¹ and Fons A.J. van de Loo¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose:: Rheumatoid arthritis (RA) is an autoimmune inflammatory disease that mainly affects synovial joints. Most research on RA has focused on cytokines as main effectors…
Abstract Number: 72 • 2017 ACR/ARHP Annual Meeting
The Presence of IgM Rheumatoid Factor Impede Immunodetection of Tnfa on Circulating Extracellular Vesicles Obtained from Rheumatoid Arthritis Patients
Onno J. Arntz¹, Bartijn C.H. Pieters¹, Rogier Thurlings², Peter M. van der Kraan³, F van den Hoogen² and Fons A.J. van de Loo³, ¹Experimental Rheumatology, Radboudumc, Nijmegen, Netherlands, ²Rheumatology, Radboudumc, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Tumor-necrosis factor (TNF)-α plays a key role in the pathophysiology of rheumatoid arthritis (RA) and membrane bound TNFα is sufficient to induce arthritis in…
Abstract Number: 239 • 2017 ACR/ARHP Annual Meeting
Ultrasound Abnormalities Predict Arthritis Development in ACPA and/or RF Positive Arthralgia Patients
Annelies Blanken¹, Marian van Beers-Tas¹, Marlies Meursinge Reynders¹ and Dirkjan van Schaardenburg^1,2, ¹Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | Academic Medical Center, Amsterdam, Netherlands
Background/Purpose: Early diagnosis of rheumatoid arthritis (RA) is important for controlling disease activity and preventing joint damage. Individuals positive for anticitrullinated protein antibodies (ACPA) and/or…
Abstract Number: 480 • 2017 ACR/ARHP Annual Meeting
ANTI-Carbamylated Protein Antibodies (CARP) in Palindromic Rheumatism: Prevalence and Clinical Significance
Raul Castellanos-Moreira Sr.¹, Virginia Ruiz-Esquide¹, María José Gomara², Sonia Cabrera-Villalba¹, Sebastian C Rodriguez-Garcia¹, Georgina Salvador³, Andrea Cuervo¹, Julio Ramírez¹, M. Victoria Hernández¹, Juan Cañete¹, Isabel Haro² and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, Barcelona, Spain, ³Hospital Universitario Mutua Terrassa, Barcelona, Spain
Background/Purpose: Autoantibodies (RF or ACPA) are found in sera from patients with palindromic rheumatism (PR) but there are no studies analyzing the presence of Anti-carbamylated…
Abstract Number: 482 • 2017 ACR/ARHP Annual Meeting
The Link between ACPA and Erosion Development: Is ACPA Sufficient? an Association Study in Clinically Suspect Arthralgia
Robin M ten Brinck¹, REM Toes² and Annette H.M. van der Helm-van Mil¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) associate with more severe joint erosions in rheumatoid arthritis (RA), but the underlying mechanism is unclear. Recent in vitro and…
Abstract Number: 1250 • 2017 ACR/ARHP Annual Meeting
Outcomes in Real-World Patients with Early Aggressive Rheumatoid Arthritis
Keith Knapp^1,2, Eric Mueller^1,2 and Gary Craig^1,2, ¹Arthritis Northwest PLLC., Spokane, WA, ²Discus Analytics LLC., Spokane, WA
Background/Purpose: The window of opportunity to address early rheumatoid arthritis (RA) in patients (pts) is well documented. However early aggressive (agr) RA needs further study…
Abstract Number: 1376 • 2017 ACR/ARHP Annual Meeting
Diagnostic Performance of 7 Different Anti-Cyclic Citrullinated Peptide Antibody and 6 Rheumatoid Factor Assays in a Primary Diagnostic, Consecutive Rheumatological Population in a Secondary Care Hospital
Lieve Van Hoovels¹, Julie Jacobs¹, Bert Vander Cruyssen², Stefanie Van den Bremt¹, Patrick Verschueren³ and Xavier Bossuyt⁴, ¹Laboratory medicine, OLV Hospital, Aalst, Belgium, ²Rheumatology, OLV hospital, Aalst, Belgium, ³Division of Rheumatology, University Hospital Leuven, Leuven, Belgium, ⁴Laboratory medicine, University Hospital Leuven, Leuven, Belgium
Background/Purpose: The clinical diagnosis of rheumatoid arthritis (RA) remains a challenge, making serological markers most interesting. The 2010 ACR/EULAR classification criteria for RA take into…
Abstract Number: 1402 • 2017 ACR/ARHP Annual Meeting
In RA, Becoming Seronegative over the 1st Year of DMARD Treatment Does Not Improve Chances of Drug-Free Remission in the Long-Term
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², Yvonne P. Goekoop-Ruiterman³, GM Steup-Beekman^1,4, Tom W.J. Huizinga⁵, Cornelia F Allaart⁵, Rene E.M. Toes¹ and Diane van der Woude⁶, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, LUMC, Leiden, Netherlands, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Patients with RA harbor autoantibodies of various isotypes and directed against several post-translational modifications. Baseline seropositivity is a poor prognostic factor for sustained drug-free…
Abstract Number: 1432 • 2017 ACR/ARHP Annual Meeting
The Prognostic Value of IgA Subtypes of Rheumatoid Factor and Anti-Citrullinated Protein Antibodies (ACPA) for Prediction of Therapeutic Responses to TNF Inhibitory Therapy in Patients with Rheumatoid Arthritis
Daniela Sieghart¹, Farideh Alasti², Paul Studenic¹ and Günter Steiner², ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Rheumatoid factor (RF) and Anti-Citrullinated Protein antibodies (ACPA) are the most specific diagnostic markers of rheumatoid arthritis (RA). These antibodies are predominantly of the…
Abstract Number: 1454 • 2017 ACR/ARHP Annual Meeting
Association of Poor Prognostic Factors with Medication Persistence Among Adult RA Patients within a Community of Rheumatology Clinics
Damemarie Paul¹, Laura McDonald², Aarti Rao³, Ruthwik Anupindi⁴ and Keith Knapp^5,6, ¹HEOR, Bristol Myers Squibb, Lawrence Township, NJ, ²CORDS, Bristol Myers Squibb, Uxbridge, United Kingdom, ³Analytics, Mu-Sigma, Bengaluru, India, ⁴Analytics, Mu-Sigma, Lawrence Township, NJ, ⁵Arthritis Northwest PLLC., Spokane, WA, ⁶Discus Analytics LLC., Spokane, WA
Background/Purpose: A fixed treatment paradigm often exists for Rheumatoid Arthritis(RA) patient(pts)1. However, RA is a heterogeneous disease and differences in pts’ serostatus affect disease progression.…
Abstract Number: 1819 • 2017 ACR/ARHP Annual Meeting
Delay of Diagnosis and Treatment in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity
Caitrin Coffey¹, Cynthia S. Crowson², Elena Myasoedova³, Eric L. Matteson⁴ and John M. Davis III⁵, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic, Rochester, MN, ⁴Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ⁵Division of Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Evidence supports a therapeutic window of opportunity in early rheumatoid arthritis (RA), during which DMARD therapy most effectively improves clinical outcomes. The 2010 ACR/EULAR…
Abstract Number: 2016 • 2017 ACR/ARHP Annual Meeting
Favourable Changes in Power Doppler Scores in the Feet over 1-Year in an Early Rheumatoid Arthritis Cohort: The Role of Rheumatoid Factor and Anti–Citrullinated Protein Antibody
Karen A. Beattie¹, Hanyan Zou², George Ioannidis³ and Maggie Larche¹, ¹Medicine, McMaster University, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³St Joseph's Healthcare Hamilton, Hamilton, ON, Canada
Background/Purpose : MTP joints are seldom examined in routine clinical visits. As such, it is important to understand how the standard treatment of patients with…
Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Corinne Kowal¹, Carey Shive^2,3, Elizabeth Zebrowski^4,5, Lenche Kostadinova^1,6, Brianna Fuller^1,6, Elane Reyes², Kelsey Rife⁴, Amy Hirsch⁴, Anita Compan⁴, Shyam Kottilil⁷, Yngve Falck-Ytter^6,8, Leonard H. Calabrese⁹, Donald Anthony^4,6,10,11 and Maya Mattar^6,12, ¹Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, ²Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, ³VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH, ⁵Department of Medicine, Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University, Cleveland, OH, ⁷IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, ⁸Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, ⁹Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ¹⁰Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, ¹¹VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, ¹²Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
Abstract Number: 2916 • 2017 ACR/ARHP Annual Meeting
The Presence of a Large Number of Autoantibodies at Baseline Is Favourable for Early Treatment Response but Unfavourable for Drug-Free Remission in RA Patients
Emma de Moel¹, Veerle Derksen¹, LA Trouw¹, Holger Bang², R.J. Goekoop³, I Speyer⁴, TWJ Huizinga¹, CF Allaart¹, REM Toes¹ and Diane van der Woude⁵, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Orgentec Diagnostika GmbH, Mainz, Germany, ³Haga Hospital, The Hague, Netherlands, ⁴Haaglanden Medical Center, The Hague, Netherlands, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The autoantibody response of seropositive RA is very diverse and consists of various numbers of isotypes and antibodies to multiple post-translational modifications. It is…

« Previous Page
1
…
5
6
7
8
9
…
11
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].